Healthcare stocks opened mixed with several biotech shares are showing heavy gains lead by AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) and Keryx Biopharmaceuticals(NASDAQ:KERX) following positive comments from Jeremy Richards.
Shares of KERX are up over 30% and AEZS popped up over 21% to $2.13 as Jeremy Richards said that companies are expected to show positive Phase 3 clinical information, to be announced within couple of weeks.
BioSante Pharmaceuticals Inc (NASDAQ:BPAX) increased 6.01% to $.806. The company said that the latest issue of The Lancet Oncology published the results from a Phase I dose escalation clinical study of GVAX Prostate cancer vaccine.
TranS1 Inc (NASDAQ:TSON) among the gainers in NASDAQ. The stock moved up 27.13% to $4.17. The Company announced that the American Medical Association Panel has voted to approve an application for a Category I CPT code for L5-S1 spinal fusion utilizing TranS1’s pre-sacral interbody fusion approach with its AxiaLIF implant.
Covidien plc (NYSE:COV) went up 0.60% to $52.27. The U.S. Food and Drug Administration approved for Solitaire FR revascularization device of Covidien plc. This helps to restore blood flow to the brain. The device mechanically removes blood clots from blocked vessels in patients with acute ischemic stroke. Covidien expects the Solitaire FR to be available in the U.S. next month.
DepoMed Inc (NASDAQ:DEPO) among the losers in NASDAQ. The stock declined 2.76% to $5.99. The company said that it has filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against three companies that have filed Abbreviated New Drug Applications with the FDA to market generic Gralise.
Merck & Co Inc (NYSE:MRK) surged up 0.95% to $38.29. The Company has received a 2012 ENERGY STAR Sustained Excellence Award from the U.S. Environmental Protection Agency for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors.
Leave a Reply